You are here: Industry Insights > Cellenkos

News List

Cellenkos Chooses Cryoport to Support Covid-19 Therapy Shipments to Patients contractpharma
June 23, 2021
Cellenkos Inc., a privately held, clinical-stage biotechnology company, has selected Cryoport to provide a staged, on-demand, logistics solution for Covid-19 therapy shipments for patients in need.
Cellenkos® Selects Cryoport to Support On-Demand, Flexible COVID-19 Therapy Shipments to Patients in Need prnewswire
June 23, 2021
Cryoport, Inc. today announced that Cellenkos®, Inc., a privately held, clinical-stage biotechnology company, has selected Cryoport to provide a staged, on-demand, logistics solution for COVID-19 therapy shipments for patients in need.
Cellenkos Announces FDA Clearance for Trial of CK0802 for COVID-19 ARDS americanpharmaceuticalreview
June 08, 2020
Cellenkos announced the US Food & Drug Administration (FDA) has cleared the way to initiate a Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome.
Cellenkos Focuses on the Development of Cell-Therapy for CoV-ARDS americanpharmaceuticalreview
March 20, 2020
Cellenkos has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority (BARDA) to start a Phase 1/2 clinical trial ...
Cellenkos to trial cell therapy for CoV-ARDS pharmaceutical-technology
March 19, 2020
Cellenkos has filed a proposal with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase I / II clinical trial of CK0802 to treat Covid-19 ...
Golden Meditech's Associate, Cellenkos, Focuses on the Development of Cell-theray for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS) prnasia
March 18, 2020
Cellenkos will leverage its clinical experience with CK0802 for other inflammatory disorders, including amyotrophic lateral sclerosisand and fast-track development of CK0802 to treat respiratory complications caused by COVID-19 infection.
Cellenkos Initiates CK0801 Trial for Bone Marrow Failure Syndromes americanpharmaceuticalreview
June 06, 2019
Cellenkos announced the initiation of a Phase 1 Clinical Trial of CK0801, a first-in-class, allogeneic cord blood-derived T-regulatory cell product, for treatment of patients with bone marrow failure syndromes...